NEW YORK--(BUSINESS WIRE)--Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, will disclose updated interim safety and efficacy data from its ongoing REP 301 trial (NCT02233075) at the 2015 meeting of the American Association for the Study of Liver Disease (AASLD) being held from November 13-17 in San Francisco, USA. Updated data from the REP 301 trial is scheduled to be presented (Abstract 31) on Sunday November 15th in Parallel Session 4: Hepatitis B: Novel Treatments and Treatment Targets.
Help employers find you! Check out all the jobs and post your resume.
